In a Sanofi ad agency rejig, the WPP Group joins Publicis and Havas as creative and media agencies across the company's business units.
Remember Doan’s for back pain? It's back, thanks to Dr. Reddy’s Laboratories, which is breathing new marketing life into a handful of older brands.
Most pharmaceutical companies work with an average of seven bioanalytical labs in a given year, taking time and scientists away from important research and…
Pfizer has rebuked U.K. drug cost watchdog NICE for its refusal to recommend approval of the drugmaker's new targeted leukemia treatment.
Merck CEO Ken Frazier's resignation from President Trump’s manufacturing council has resonated positively across a broad audience.
Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.
Sorry, Tesaro. AZ's Lynparza won a broader-than-expected approval in ovarian cancer, putting it on even footing with Tesaro’s recent launch, Zejula.…
Reps. Elijah Cummings and Peter Welch announced a new probe into multiple sclerosis drug costs, digging into price hikes from seven pharmas.
Mylan has finished a settlement with the Department of Justice for $465 million relating to EpiPen’s misclassification on Medicaid.
Pfizer today won FDA approval for a new targeted drug for the treatment of relapsed or refractory acute lymphoblastic leukemia.
Martin Shkreli, who was convicted two weeks ago of federal criminal securities fraud, says he doesn’t think he will go to prison.